Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 7, Issue 10, Pages 604-608Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2010.118
Keywords
-
Categories
Funding
- Swedish Research Council
- Swedish Cancer Foundation
- Karolinska Institute Foundation
- Karolinska Institute Distinguished Professor Award
- European Union [222741]
- European Research Council (ERC) [250021]
Ask authors/readers for more resources
Antiangiogenic cancer therapy is based on agents that target blood vessels of the tumor to inhibit its growth. However, experience from the clinic demonstrates that survival benefits following antiangiogenic therapy do not always correlate with tumor size and growth inhibition. Emerging evidence shows that delivery of antiangiogenic drugs might induce systemic alterations of the vasculature that modulate the function of various tissues and organs. Normalization of tissues and organs by antiangiogenic therapy may be an important mechanism underlying the survival benefits seen in patients with cancer who suffer cancer-associated systemic syndromes. This new concept has been validated in preclinical tumor models, and responses in patients have positively correlated with clinical benefits.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available